Challenge Grants: Biodefense Product Development

The summary for the Challenge Grants: Biodefense Product Development grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Challenge Grants: Biodefense Product Development: Research supported and conducted by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, strives to understand, treat and ultimately prevent the myriad infectious, immunologic, and allergic diseases that threaten millions of human lives. The NIAID Division of Microbiology and Infectious Diseases (DMID) and the Division of Allergy, Immunology and Transplantation (DAIT) support extramural research to control and prevent diseases caused by virtually all infectious agents. This includes basic biomedical research, such as studies of microbial physiology and antigenic structure; immunity; applied research, including the development of diagnostic tests; and clinical trials to evaluate experimental drugs and vaccines. In response to growing concerns about the use of biological agents in acts of terrorism, the further clinical development of new vaccines, therapeutics, adjuvants, and diagnostics against NIAID Category A, B, and C priority pathogens (see http://www.niaid.nih.gov/biodefense/bandc_priority.htm) is a high priority. This program, CHALLENGE GRANTS: BIODEFENSE PRODUCT DEVELOPMENT, will support further development of previously identified products against NIAID Category A, B, and C high priority pathogens including vaccines, adjuvants, therapeutics, and diagnostics. To be responsive to this program for the development of biodefense products, the applicant must have already demonstrated proof-of-principle for a candidate vaccine, therapeutic, adjuvant, or diagnostic method for biodefense. Phases of further development eligible for support include, but are not limited to: early validation; pre- clinical stages; scale-up; production; and fulfilling regulatory requirements. NOTE: While clinical development strategies may be included within an overall development plan, this RFA will NOT support clinical trials; applications requesting support for clinical trials will be viewed as unresponsive to this RFA and will be returned without review. Utilization of human derived material in pre-clinical studies in support of complying with regulatory requirements is considered responsive. NOTE: Applications to support basic research or the "discovery" of new targets or the identification and validation of protective epitopes for NIAID Category A, B, and C priority pathogens will NOT be supported under this RFA, but are supported by other NIAID programs (see http://www.niaid.nih.gov/biodefense/research/funding.htm). In addition, ancillary research studies that are not directly relevant to development of the selected product will not be supported. Challenge Grants Under this program, Challenge (UC1) grant awards will be performance based for a period of up to three years. That is, funds can be requested and will be awarded in increments based on the attainment of interim research objectives (milestones) defined by the applicant and approved following peer review by the NIAID. Because funding will be tied to the attainment of interim research objectives (milestones), funding will not be provided annually as is traditional for NIH grants, but will be linked to project timelines and interim objectives. Initial release of funds will be to support achievement of the first interim objective/milestone. Release of the next funding increment will be based on the achievement of the previous interim objective, as determined by NIAID staff. Partnerships A key component of this initiative is the development of partnerships between the government and industry. For the purpose of this program, "industry" is defined as large and small, domestic or foreign, pharmaceutical, biotechnology, bioengineering, and chemical companies. Since academic organizations are often the source of new candidate products, this program can also support a partnership between industry and collaborator(s) as necessary from academic and non-profit research organizations. The involvement of an academic or non-profit research organization is NOT a requirement; therefore, industry does not need an academic collaborator to submit an application to this program. All projects must demonstrate substantive investment by industry participant(s). "Substantive investment" is defined, for the purposes of this program, as substantive commitment of any one or more of the following resources: personnel, in kind contributions of materials and/or reagents, including but not limited to chemical libraries, innovative biotechnology platforms (i.e., for screening of drugs and inhibitors), scale up of GMP chemical synthesis or production, provision of animal or other laboratory models for evaluation, subcontracts, data management resources, regulatory support, and alterations/renovations of facilities or provision of equipment to address biohazard concerns. The Principal Investigator of the project may be affiliated with either industry or an academic organization (if academia is part of a partnership with industry). See information under ELIGIBLE INSTITUTIONS below.
Federal Grant Title: Challenge Grants: Biodefense Product Development
Federal Agency Name: National Institutes of Health
Grant Categories: Health
Type of Opportunity: Discretionary
Funding Opportunity Number: RFA-AI-04-029
Type of Funding: Cooperative Agreement
CFDA Numbers: 93.85593.856
CFDA Descriptions: Allergy, Immunology and Transplantation Research 93.856 Microbiology and Infectious Diseases Research
Current Application Deadline: No deadline provided
Original Application Deadline: Jan 18, 2005
Posted Date: Jun 21, 2004
Creation Date: Jun 21, 2004
Archive Date: Feb 17, 2005
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Applicants Eligible for this Grant
County governments City or township governments State governments Special district governments Independent school districts Public and State controlled institutions of higher education Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education For profit organizations other than small businesses Small businesses
Link to Full Grant Announcement
Information not provided
Grant Announcement Contact
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [email protected] NIH OER Webmaster